The trial compared Lynparza with chemotherapy (physician’s choice of capecitabine, eribulin or vinorelbine) for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival (PFS). Read More »

The Centers for Disease Control and Prevention (CDC) has issued an outbreak alert informing clinicians about reports of potentially life-threatening hemorrhage associated with the use of synthetic cannabinoids. Read More »

The unprecedented progression-free survival benefit for 1st-line Tagrisso demonstrated in the FLAURA trial is preserved through subsequent lines of therapy Read More »

Hospitals that are visited by surveyors from the Joint Commission need to demonstrate the existence of and adherence to policies for reviewing overrides for medications kept in automated dispensing cabinets (ADCs). Read More »

Just announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite. The asset transfer was completed on April 12, 2018. Additional financial information or further deal terms are not being disclosed. Read More »

In reviewing several legislative proposals to combat the nation’s opioid crisis, members of a House of Representatives subcommittee on February 28 opined on the need for healthcare providers to receive special training on prescribing and dispensing opioid-containing products. Read More »

An a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, is supporting the presentation of three accepted scientific presentations at the National Lipid Association (NLA) Scientific Sessions in Las Vegas, NV, April 26-29, 2018. Read More »

A hearing of the House Energy and Commerce Committee’s health subcommittee on the opioid epidemic, Rep. Cathy McMorris Rodgers (R-Wash.) discussed the pharmacist’s role in delivering patient care to Medicare beneficiaries and noted her support for legislation that allows pharmacists to care for patients in certain underserved areas. Specifically, she mentioned the benefits of H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act, and submitted a letter of support from the Washington Pharmacy Association. Read More »

Just announced full results from the Phase 3b LIBERTY trial of Aimovig™ (erenumab) in episodic migraine patients who had previously failed two to four preventive treatments, due to lack of efficacy or to intolerable side effects. Read More »

ASHP’s 2018 Match concluded today, as 4,777 individuals matched with more than 2,300 pharmacy residency programs across the country. Read More »

AbbVie (NYSE: ABBV) announced global resolution of all intellectual property-related litigation with Samsung Bioepis over its proposed biosimilar adalimumab product. Read More »

These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein (hsCRP) levels, and persistent high triglycerides (TG) despite statin therapy due to the association with increased cardiovascular disease (CVD) risk. Read More »

Acorda Therapeutics, Inc. will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 21–27, 2018. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Read More »

As part of Aetna’s commitment to enhancing access to evidence-based addiction treatment options for its members, medication-assisted treatment (MAT) is available for those with opioid use disorder. Read More »

A research-based global biopharmaceutical company, will participate in the Deutsche Bank's 43rdAnnual Health Care Conference on Wednesday, May 9, 2018. Bill Chase, executive vice president and chief financial officer, will present at 7 a.m. Central time. Read More »

Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand access to medicine, commitment to complex scientific programs and commercial diversification, and significant financial flexibility. Additionally, the presentation highlights recently announced opportunities, including: Read More »

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the House Energy and Commerce Health Subcommittee’s hearing Combating the Opioid Crisis: Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has acquired global development and marketing rights from Prayog Labs LLC to bring to market a fast-acting Meloxicam as a proposed non-narcotic analgesic. Read More »

Just announced that John Renger, Ph.D., has been appointed Vice President, Head of Research & Development and Regulatory Affairs. He will be based in Stamford, Connecticut and report directly to President and CEO Craig Landau, MD. Read More »